Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 586 Shares

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 586 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $225.00, for a total value of $131,850.00. Following the transaction, the director now directly owns 14,722 shares of the company’s stock, valued at $3,312,450. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Laboratory Co. of America Trading Down 0.8 %

Laboratory Co. of America stock traded down $1.69 during mid-day trading on Friday, hitting $223.05. The company’s stock had a trading volume of 30,021 shares, compared to its average volume of 721,322. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88. The company has a 50 day moving average of $207.57 and a 200-day moving average of $210.54. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $238.46. The stock has a market cap of $18.80 billion, a PE ratio of 45.22, a P/E/G ratio of 1.76 and a beta of 1.05.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.78 by $0.16. The company had revenue of $3.22 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Laboratory Co. of America had a net margin of 3.60% and a return on equity of 15.39%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $3.42 EPS. On average, research analysts anticipate that Laboratory Co. of America Holdings will post 14.84 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Thursday, August 29th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date of this dividend is Thursday, August 29th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%.

Hedge Funds Weigh In On Laboratory Co. of America

Hedge funds and other institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC bought a new position in shares of Laboratory Co. of America in the 4th quarter worth $5,838,000. Bleakley Financial Group LLC boosted its stake in Laboratory Co. of America by 2.8% in the fourth quarter. Bleakley Financial Group LLC now owns 2,310 shares of the medical research company’s stock valued at $525,000 after acquiring an additional 64 shares in the last quarter. HBK Sorce Advisory LLC purchased a new position in Laboratory Co. of America in the fourth quarter worth $213,000. Tobam lifted its holdings in shares of Laboratory Co. of America by 162.5% during the 4th quarter. Tobam now owns 911 shares of the medical research company’s stock valued at $207,000 after purchasing an additional 564 shares during the last quarter. Finally, Cerity Partners LLC boosted its position in shares of Laboratory Co. of America by 8.6% in the 4th quarter. Cerity Partners LLC now owns 64,435 shares of the medical research company’s stock worth $14,645,000 after purchasing an additional 5,105 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LH. Barclays increased their target price on Laboratory Co. of America from $213.00 to $249.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Bank of America increased their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Laboratory Co. of America from $220.00 to $230.00 and gave the stock a “hold” rating in a report on Friday, August 2nd. Robert W. Baird lifted their price target on Laboratory Co. of America from $261.00 to $277.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Finally, Evercore ISI boosted their price objective on Laboratory Co. of America from $210.00 to $215.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 9th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.15.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).